Estradiolcypionate administered at the end of a progesterone-based protocol for FTAI induces ovulation and improves postovulatory luteal function and uterine environment in anestrous beef cows. The objective of this study was to evaluate the effect of the administration of estradiolcypionate (ECP) at the end of an estradiol and progesterone-based protocol for fixed time artificial insemination
EstradiolCypionate An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM Levels and EffectsSummary of Use during LactationEstradiol cypionate has not been studied during breastfeeding. However, a similar drug, estradiol valerate, has been used to suppress lactation, usually in combination with testosterone. Generally, estradiolcypionate should be avoided in mothers wishing to breastfeed, especially if started before the milk supply is well established at about 6 weeks
Treatment with estradiolcypionate at progesterone withdrawal reduces handling without compromising the pregnancy rate to timed-AI in buffalo. The aim of this study was to determine if treatment with estradiolcypionate (EC) at the time of P4 withdrawal induced ovulation in a synchronization/timed-AI (TAI) protocol in buffalo. In Experiment 1, 56 buffaloes received an intravaginal P4 device (1.0
Impact of estradiolcypionate prior to TAI and progesterone supplementation at initial diestrus on ovarian and fertility responses in beef cows. In cattle, early diestrus progesterone (P4) supplementation modulates endometrial function to exert pro- and anti-pregnancy establishment effects; specifically, P4 stimulates conceptus growth, but also induces early onset of luteolysis. This paradoxical (Bos indicus) were synchronized with an E2/P4-based protocol for TAI and assigned to receive 1.0 mg of estradiolcypionate (CP) or nothing (NoCP) on D-2 and 150 mg of injectable long-acting P4 (iP4) or Placebo (NoiP4) on D4 on a 2 × 2 factorial arrangement. On D15, the iP4 supplementation increased (P < 0.05) the frequency of early luteolysis (NoCP + iP4: 26.0%; [13/50] vs. NoCP: 8.0% [4/50]), but CP
Optimizing timed AI protocols for Angus beef heifers: Comparison of induction of synchronized ovulation with estradiolcypionate or GnRH. This study compared estradiolcypionate (ECP) or GnRH as ovulation inducers at the end of a timed AI (TAI) protocol in Angus heifers. On day 0, heifers (n = 415), between 22 and 24 months of age, were treated with an intravaginal 1 g progesterone (P4) insert
Progesterone-based fixed-time artificial insemination protocols for dairy cows: Gonadotropin-releasing hormone versus estradiol benzoate at initiation and estradiolcypionate versus estradiol benzoate at the end. Our objectives were to evaluate ovarian dynamics and fertility comparing 2 treatments at the start of a progesterone (P4)-based fixed-time artificial insemination (FTAI) protocol and 2 treatments at the end of the protocol. Thus, 1,035 lactating Holstein cows were assigned in a random phase of the estrous cycle to 1 of 4 treatments using a completely randomized design with a 2×2 factorial arrangement. At the beginning of the protocol (d -10), cows received GnRH or estradiol benzoate (EB) and, at the end, EB (d -1) or estradiolcypionate (ECP; d -2), resulting in 4 treatments: GnRH-EB
Estradiolcypionate aided treatment for experimentally induced ascending placentitis in mares. The overall goal of this study was to assess the efficacy of various therapeutic combinations of estradiolcypionate (ECP, a long-acting estrogen) and altrenogest (ALT, a long-acting progestin) in addition to basic treatment for placentitis with trimethoprim-sulfamethoxazole (TMS) and flunixin meglumine
Effect of estradiolcypionate and GnRH treatment on plasma estradiol-17β concentrations, synchronization of ovulation and on pregnancy rates in suckled beef cows treated with FTAI-based protocols. Two experiments were conducted to evaluate the effect of different ovulation inducers on E-17β plasma concentrations, synchronized ovulations and pregnancy rates. In Experiment 1, cows received a progesterone intravaginal device (PID) with 1 g of progesterone (P4) plus 2 mg of estradiol benzoate (EB) (day 0). At PID removal (day 8), cows received 0.150 mg of D-cloprostenol and were randomly assigned to four treatment groups (n = 10/treatment): Group ECP: 1 mg of estradiolcypionate at PID removal, Group EB: 1 mg of EB 24 hr after PID removal, Group GnRH: 10 μg of GnRH 48 hr after PID removal, Group
Effect of estradiolcypionate and amount of progesterone in the intravaginal device on synchronization of estrus, ovulation and on pregnancy rate in beef cows treated with FTAI based protocols. Three experiments were conducted to evaluate the effect of estradiolcypionate (ECP) and amount of progesterone in the intravaginal device (PID) on synchronization of estrus and ovulation, follicular
preparations of compounded bioidentical menopausal hormone therapy include estrone, estradiolcypionate, estriol, pregnenolone, testosterone, testosterone cypionate, and testosterone propionate 1. Many compounding pharmacies use the phrase “bioidentical hormone” as a marketing term to imply that these preparations are natural and, thus, safer and more effective than FDA-approved menopausal medications
treated with 2.0 mg i.m. of EB and 16.8 µg i.m. of buserelin acetate (GnRH), while in Group GnRH, cows received only 16.8 µg i.m of GnRH. Seven d later (d 7), 0.530 mg i.m. of cloprostenol sodium (PGF) was administered in all cows, followed by a second dose on d 8, concomitant with 1.0 mg i.m. of estradiolcypionate (EC) and P4 implant withdrawal. The TAI was performed on d 10 (48 h after P4 device
and 147 multiparous cows) with a body condition score between 3.0 and 4.0, were submitted to the TET protocol consisting of an intramuscular (i.m.) injection of 2.0 mg estradiol benzoate (EB) and the insertion of intravaginal progesterone (P4) device that remained until Day -2.5. On the same day (-2.5), the recipients received i.m. 150 mg D-cloprostenol and 1 mg estradiolcypionate and were randomly
Plasma Estradiol Profile After Administration of Different Types of Estradiol Esters in Acyclic Mares. Although the use of different estradiol esters has been extensively studied in hormonal protocols in cows, such information is lacking in mares. The present study aimed to assess the effects of treatment with the same doses and administration frequency of estradiolcypionate, estradiol benzoate and 17β estradiol on plasma estradiol (E2) concentrations of acyclic mares and correlate the E2 profile to the endometrial edema score. Sixteen treatments were performed in 14 mares randomly divided into three groups: EB (n = 5), EC (n = 5), and 17β (n = 6), receiving 10 mg on day 0 (D0), 6 mg on D1, and 4 mg on D2 of estradiol benzoate, estradiolcypionate, and estradiol 17β, respectively. Blood
of EB plus 100 µg of gonadorelin diacetate tetrahydrate (GnRH) i.m.; and cows in the EBd0-GnRHd2 group received 2 mg of EB on d 0 and 100 µg of GnRH 48 h later (d 2). The remaining treatments in the protocol were similar among groups and included 0.53 mg (i.m.) of cloprostenol sodium (PGF) on d 7, followed by a second PGF treatment on d 9 (at the time of P4 implant withdrawal) and 1 mg of estradiolcypionate i.m. Then, TAI was performed on d 11 (48 h after P4 removal) in all experimental groups. We detected an effect of treatment on pregnancy per AI (P/AI) on d 30, in which cows from the EBd0-GnRHd2 group demonstrated greater fertility than EBd0 cows, whereas cows in the EBd0-GnRHd0 group did not differ among EBd0 and EBd0-GnRHd0 (40.5 vs. 30.4 vs. 34.4%, respectively). In summary, GnRH treatment
at random to two experimental groups: non-treated gilts (CON, n = 22), serving as controls, and prolonged luteal function group (CYP, n = 30), receiving a single treatment with 10 mg of estradiolcypionate intramuscularly Starting on day 12, blood samples were collected for estradiol and progesterone assays. Estrus detection started on day 17. Gilts from the CON group were inseminated at the onset of natural estrus. On day 28 CYP gilts were treated with PGF2α to induce luteolysis and inseminated at the onset of estrus. Gilts were slaughtered 5 d after the last insemination. A single treatment with estradiolcypionate prolonged luteal function in 90% of treated gilts. The duration of the estrous cycle was longer (p < 0.0001) for CYP gilts compared to CON gilts. CYP gilts showed synchronized estrus
in virgin rats, after treatment with LOO for three consecutive days, was carried out by the construction of a concentration-response curve with oxytocin or carbachol. The primary dysmenorrhea animal model was replicated with an injection of estradiolcypionate in female mice for three consecutive days, followed by intraperitoneal application of oxytocin. LOO relaxed the rat uterus precontracted with 10 IU
artificial insemination (FTAI). In Experiment 1, 20 non-lactating beef cows were treated with 2 mg estradiol benzoate (EB) and an intravaginal device containing 0.5 g of P4. Seven days later, P4 devices were removed and all cows received prostaglandin F2 alpha (PGF) and 0.5 mg estradiolcypionate (ECP). Estrus was detected using tail paint and cows that did not show estrus by 48 h after P4 device removal